- Home
- GABC vs MYGN Comparison
GABC vs MYGN Comparison
Compare GABC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GABC
- MYGN
- Stock Information
- Founded
- GABC 1910
- MYGN 1991
- Country
- GABC United States
- MYGN United States
- Employees
- GABC N/A
- MYGN N/A
- Industry
- GABC Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GABC Finance
- MYGN Health Care
- Exchange
- GABC Nasdaq
- MYGN Nasdaq
- Market Cap
- GABC 1.2B
- MYGN 1.3B
- IPO Year
- GABC N/A
- MYGN 1995
- Fundamental
- Price
- GABC $38.90
- MYGN $10.18
- Analyst Decision
- GABC Buy
- MYGN Hold
- Analyst Count
- GABC 4
- MYGN 15
- Target Price
- GABC $46.00
- MYGN $21.30
- AVG Volume (30 Days)
- GABC 117.1K
- MYGN 1.3M
- Earning Date
- GABC 04-28-2025
- MYGN 02-24-2025
- Dividend Yield
- GABC 2.98%
- MYGN N/A
- EPS Growth
- GABC N/A
- MYGN N/A
- EPS
- GABC 2.83
- MYGN N/A
- Revenue
- GABC $250,476,000.00
- MYGN $837,600,000.00
- Revenue This Year
- GABC $42.75
- MYGN $5.48
- Revenue Next Year
- GABC $7.67
- MYGN $9.17
- P/E Ratio
- GABC $13.76
- MYGN N/A
- Revenue Growth
- GABC 0.94
- MYGN 11.21
- 52 Week Low
- GABC $31.06
- MYGN $9.76
- 52 Week High
- GABC $47.08
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GABC 40.13
- MYGN 28.83
- Support Level
- GABC $39.00
- MYGN $10.10
- Resistance Level
- GABC $40.33
- MYGN $10.68
- Average True Range (ATR)
- GABC 0.83
- MYGN 0.80
- MACD
- GABC -0.09
- MYGN -0.30
- Stochastic Oscillator
- GABC 28.33
- MYGN 7.36
About GABC German American Bancorp Inc.
German American Bancorp Inc is a bank holding company. The Company's lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.